R R

What Is Rybrevant?

Rybrevant is a prescription targeted cancer medication containing amivantamab-vmjw, a bispecific monoclonal antibody directed against epidermal growth factor receptor, or EGFR, and MET. It is used to treat selected adults with locally advanced or metastatic non-small cell lung cancer carrying specified EGFR mutations. Rybrevant is administered by intravenous infusion and may be prescribed alone or with other cancer medications depending on the tumor's genetic characteristics and previous treatment. It is distinct from Rybrevant Faspro, a subcutaneous combination of amivantamab and hyaluronidase with different administration instructions. Rybrevant requires monitoring for infusion reactions, lung inflammation, skin problems, and eye-related adverse effects.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Rybrevant?

Rybrevant is a prescription targeted cancer medication containing amivantamab-vmjw, a bispecific monoclonal antibody directed against epidermal growth factor receptor, or EGFR, and MET. It is used to treat selected adults with locally advanced or metastatic non-small cell lung cancer carrying specified EGFR mutations. Rybrevant is administered by intravenous infusion and may be prescribed alone or with other cancer medications depending on the tumor's genetic characteristics and previous treatment. It is distinct from Rybrevant Faspro, a subcutaneous combination of amivantamab and hyaluronidase with different administration instructions. Rybrevant requires monitoring for infusion reactions, lung inflammation, skin problems, and eye-related adverse effects.

read more about rybrevant ...

Copy this HTML:

Copy HTML Copied!

How Does Rybrevant Work?

Rybrevant binds to EGFR and MET, two cell-surface proteins involved in signaling pathways that can promote tumor growth and survival. Certain mutations in the EGFR gene cause abnormal signaling that encourages non-small cell lung cancer cells to multiply. Amivantamab interferes with EGFR and MET signaling and can promote the destruction of targeted cancer cells through immune-mediated mechanisms. Its effectiveness depends on the tumor's specific genetic alteration and the treatment regimen. Rybrevant does not treat all types of lung cancer or replace genetic testing. Its effects on normal tissues expressing EGFR can also contribute to skin and ocular adverse reactions.

What Type of Lung Cancer Does Rybrevant Treat?

Rybrevant is approved for selected adults with locally advanced or metastatic non-small cell lung cancer containing EGFR alterations. It may be combined with lazertinib as initial treatment for tumors with EGFR exon 19 deletions or exon 21 L858R mutations. It may also be combined with carboplatin and pemetrexed after progression on an EGFR tyrosine kinase inhibitor in eligible patients with those mutations. For EGFR exon 20 insertion mutations, Rybrevant is approved with carboplatin and pemetrexed as initial treatment and as a single agent after progression on platinum-based chemotherapy. Appropriate genetic testing is required to confirm treatment eligibility.

How Is Rybrevant Administered?

Rybrevant is administered through intravenous infusion by trained healthcare professionals. The dose and treatment schedule depend on the regimen and baseline body weight. When used alone or with lazertinib, treatment commonly begins with weekly administration during the initial phase, followed by infusions every two weeks. Combination treatment with carboplatin and pemetrexed follows a different schedule, generally involving infusions every three weeks after initial dosing. The first infusion is divided over two consecutive days to reduce infusion-related reactions. Patients receive appropriate medications before treatment, including antihistamines, fever-reducing drugs, and corticosteroids when indicated. Monitoring continues during infusion and throughout therapy.

What Are the Side Effects and Warnings of Rybrevant?

Common adverse effects include rash, nail inflammation, infusion-related reactions, fatigue, swelling, nausea, and reduced appetite. Serious risks include interstitial lung disease or pneumonitis, severe skin reactions, and ocular toxicity, including keratitis. When Rybrevant is combined with lazertinib, serious venous blood clots, including pulmonary embolism, can occur, and preventive anticoagulation is recommended during the first four months. Patients should use sun protection and report skin changes during treatment. New cough, worsening shortness of breath, chest pain, leg swelling, or sudden eye pain and blurred vision requires prompt assessment. Rybrevant can also harm an unborn baby.

Common Questions About Rybrevant

Is Rybrevant the same as amivantamab?

Yes. Rybrevant contains amivantamab-vmjw, a bispecific antibody that targets EGFR and MET in selected non-small cell lung cancers.

Does Rybrevant require genetic testing?

Yes. Eligibility depends on specific EGFR mutations confirmed through appropriate testing. The required mutation varies by treatment regimen.

Is Rybrevant the same as Rybrevant Faspro?

No. Rybrevant is administered intravenously, while Rybrevant Faspro contains amivantamab with hyaluronidase for subcutaneous administration. Their dosing instructions differ.

Can Rybrevant affect eyesight?

Yes. Rybrevant can cause ocular toxicity, including keratitis and other eye problems. Patients should promptly report eye pain, redness, or changes in vision.

References

Amivantamab-vmjw. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/amivantamab-vmjw. Date Accessed November 4, 2026.

Amivantamab-vmjw Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a621034.html. Date Accessed November 4, 2026.

DailyMed - RYBREVANT (amivantamab-vmjw) injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1466c070-9f97-4fa4-a955-6a6b59981fb8. Date Accessed November 4, 2026.

RYBREVANT Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761210s008lbl.pdf. Date Accessed November 4, 2026.

Rybrevant. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant. Date Accessed November 4, 2026.